1 / 21

Extraskeletal Myxoid Chondrosarcoma

Extraskeletal Myxoid Chondrosarcoma. An overview from a clinical and basic science perspective 1. Clinical case and overview. Robert Maki, Memorial Sloan-Kettering Cancer Center, New York, NY. Case presentation.

ross-wagner
Download Presentation

Extraskeletal Myxoid Chondrosarcoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Extraskeletal Myxoid Chondrosarcoma An overview from a clinical and basic science perspective 1. Clinical case and overview Robert Maki, Memorial Sloan-Kettering Cancer Center, New York, NY

  2. Case presentation • 64 M with a two-year history of a >10 cm para-testicular perineal mass causing discomfort when sitting • Hypertension only pertinent medical history, no significant family, social history. • Exam, ultrasound → Complex cystic and solid mass. • 01 / 2000: Resected with radical orchiectomy with portions of left corpus cavernosum and pubis (15 cm tumor, 1300 gram specimen).

  3. Case, continued. • Dx: EMC, t(9;22) positive, margins grossly positive, with lung metastases noted • 04/2000: Local tumor recurred, complicated by cutaneous fistula to urethra that slowly healed • Mass grew further, mostly in perineum

  4. CT 1/19/2000

  5. 4/12/00 CT of recurrence site

  6. EMC 4/26/00

  7. CT 8/16/00

  8. Case, continued. • 9/00-11/00: doxorubicin 75 mg/m2 x 3 cycles – no change • Declined further systemic therapy • Later agreed to thalidomide up to 300 mg a day but he had no benefit • Asymptomatic despite increasing size of lung metastases for the remainder of his life

  9. 2/20/01

  10. 5/31/02

  11. Patient history, conclusion • 07/02: Motor vehicle accident: found with CNS lesions, (largest 4.1 cm parietal mass): biopsy = glioblastoma multiforme • Therapy: whole brain XRT, glucocorticoids; patient declined an operation • Died of GBM 03/03

  12. EMC: Extraskeletal Myxoid Chondrosarcoma • Rare, perhaps 1-2% of sarcomas • First described in 1953 by Stout and Verner, more clearly defined by Enzinger and Shiraki in 1972 • M : F ~ 2 : 1, peak incidence ~ age 50 • Thigh and popliteal fossa most common sites (like myxoid liposarcoma) • Somewhat similar to myxoid liposarcoma microscopically • Prolonged course with local recurrences and late metastases

  13. EMC • Largest study 117 pts, 6-89 yrs old (median 52), median size 7 cm (1-25 cm) • 80% proximal extremities, limb girdles • 99 cases with follow up, median 9 yrs • 48 NED, 23 AWD, 18 DOD • Local recurrence in 48% (40/83), mets in 46% (35/76 patients) • Grading not of prognostic value in this series • Microscopically identical tumor appears in bone, but in bone it has no specific translocation and lower risk of metastasis Meis-Kindblom JM et al. Am J Surg Path 1999; 23:636 Antonescu C et al. Cancer 1998; 83:1504

  14. Extraskeletal myxoid (chondrosarcoma)? • Not chondroid at all: • Cells most frequently do not show chondroid differentiation • Cells are S100 negative, typically • EM: cells not particularly chondrocytic, but more primitive • Collagen expression • Little collagen II, no collagen X, like chondrocytes have • More typically collagens I, III, VI positive, like fibroblasts • May represent a primitive mesenchymal precursor • Rules out relationship to mesenchymal chondrosarcoma, standard chondrosarcoma, and chordoma Aigner T et al. Mod Pathol 2004; 17: 214

  15. 3 typical microscopic views of EMC Meis-Kindblom JM et al Am J Surg Path 1999; 23:636

  16. Differential pathologic diagnosis • mixed myoepithelial tumors • chondroid lipoma • myxoid liposarcoma • myxofibrosarcoma • fibromyxoid sarcoma • myxoid variants of ossifying fibromyxoid tumor • of soft parts • myxoid sclerosing epithelioid fibrosarcoma

  17. Local and metastatic risk, overall survival Local recurrence risk Risk of metastases 60% Overall Survival at 15 years, ?disease specific Overall survival Meis-Kindblom JM et al. Am J Surg Path 1999; 23:636

  18. Therapy • Surgery, ?radiation • Chemotherapy appears entirely ineffective • MD Anderson experience: 11 cases, 30 yrs • 10 cm median size, 10/11 received chemotherapy, median 4 cycles • Doxorubicin-based • Dacarbazine-based • Three received ifosfamide, no response • One patient in Winnipeg, MB received IFN-alfa-2b with a response Patel SR et al. Am J Clin Oncol 1995; 18:161 Rubinger M et al. Chest 1995; 108:281

  19. EMC typical translocation t(9;22)

  20. EMC translocation • t(9;22) EWS-TEC • TEC also called NR4A3, NOR1, MINOR, CHN • Seen in 75% of EMC • Fusion protein links trans-activation domain of EWS to entire TEC protein, an orphan nuclear steroid/thyroid receptor gene superfamily member • Less common: t(9;17)(q22;q11) TAF2N-TEC (15%), rare t(9;15) TCF12-TEC.

  21. EMC Therapy • Given the lack of viable options, one hopes that understanding of the molecular events associated with EMC will lead to better therapy

More Related